Table 1 Patient clinical data and treatment response.

Variables	No. (n = 68)	% of patients
(A) Clinical data
Age
Children (<18 years)	40	58.8
Adults	28	41.2
EMD
Present	22	32.4
Absent	46	67.6
HCT
Pre	37	54.4
Post	31	45.6
CAR-T type
CD-19	54	79.4
CD-22^a	14	20.6
CRS
0	4	5.9
I	10	14.7
II	44	64.7
III	10	14.7
Neurotoxicity (≥ grade 2)	5	7.4
GVHD after CART in post-HCT patients (n = 31)	6	19.4
Steroids^b
Not received	26	38.2
Received	42	61.8
High dose^c	23	54.8
≤7days	33	78.6
8–16 days	9	21.4

Treatment response	Steroid group (n = 42)		Non-steroid group (n = 26)
Treatment response	No.	%	No.	%	p-value
(B) Treatment response on D30 after T-cell infusion
CR/CRi	40	95.2	24	92.3	0.344
MRD-CR	32	80.0	19	79.2	0.249
PR	2	4.8	1	3.8
NR	0	0.0	1	3.8

EMD extramedullary disease, HCT hematopoietic cell transplantation, CRS cytokine release syndrome, GVHD graft-versus-hos disease, CR complete remission, CRi CR with incomplete count recovery, MRD minimal residual disease, PR partial remission, NR no remission.
^a14 patients, who failed or relapsed after CD-19 CART, or had dim CD-19 but normal CD-22 antigen expression, received CD-22 specific CAR-T therapy.
^bUsed within 1 month after T cell infusion, for all of 10 patients with grade III CRS, 68.2% (30/44) with grade II CRS, and 2 cases with no CRS but GVHD (1 case) or neurotoxicity (1 case).
^c≥10 mg/m²/d dexamethasone or equivalent.

Quick links

Search